BioFreedom proven in LEADERS FREE for Ultra-short DAPT
August 31, 2018 | News | BioFreedom
Freedom to treat with 1 month DAPT - Proven for ultra-short DAPT in the LEADERS FREE study, BioFreedom was more safe and effective than a BMS in high bleeding risk patients
HIGH BLEEDING RISK PATIENTS
January 20,2010 | News | BioFreedom
BioFreedom is the only active stent with CE mark for
ultra-short 1 month DAPT, in High bleeding Risk (HBR)
patients, supported by clinical data from a double-blind
randomized controlled trial.
ELDERLY PATIENTS WITH HIGH BLEEDING RISK
February 26,2018 | News | BioFreedom
In the pre-specified elderly subgroup of LEADERS FREE,
when considering age over 75 as sole criteria,
BioFreedom demonstrated a 0.7% definite or probable
stent thrombosis rate at one year.